Amniotic tissue provides a fertile substrate to dermal cells (including fibroblasts) to aid in skin healing. In-vitro data indicates that Axolotl Dualgraft supports fibroblast attachment and infiltration when placed on damaged tissue – this histological image demonstrates cellular attachment using an in-vitro model where fibroblasts were seeded and imaged 12-hours later.
Cross-sectional image of Dermal Fibroblasts infiltrating Amnion Graft, Ingraldi, 2023
Amniotic tissue contains many extracellular matrix components found in dermal tissue. Axolotl DualGraft™ contain Hyaluronic Acid, Collagen I, III, V & IV, Laminin, Fibronectin and Proteoglycans sterilized to reduce the risk of immunogenicity. These components provide mechanical properties similar to native tissue in terms of elasticity, flexibility, stability, and permeability.
Axolotl Graft™ and Axolotl DualGraft™ are indicated as a wound covering and structural barrier. Axolotl graft products are processed through minimal manipulation techniques, retaining the native qualities of the amniotic membrane to function as a wound covering and as a structural barrier.
Axolotl Graft™ and Axolotl DualGraft™ are dehydrated human amnion membrane allografts derived from the amniotic lining of the placenta. The donor tissue is recovered and processed under sterile conditions, in accordance with all FDA guidelines and quality assurance standards in a controlled environment. Our allograft tissue products are terminally irradiated in the final package.
Axolotl graft products have received a letter of recommendation from the FDA Tissue Reference Group (TRG) and are manufactured in an AATB accredited manufacturing environment.
Axolotl Graft™ and Axolotl DualGraft™ are marketed under Section 361 of the PHS act and regulated under 21 CFR Part 1271. Our allograft products are only intended for use in the United States.
Features & Benefits
Storage & Handling
Donor Screening